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Forkhead box O (FoxO) proteins and thyroid hormone (TH) have well established roles in
cardiovascular morphogenesis and remodeling. However, specific role(s) of individual FoxO
family members in stress-induced growth and remodeling of cardiomyocytes remains
unknown. Here, we report that FoxO1, but not FoxO3, activity is essential for reciprocal
regulation of types II and III iodothyronine deiodinases (Dio2 and Dio3, respectively), key
enzymes involved in intracellular TH metabolism. We further show that Dio2 is a direct
transcriptional target of FoxO1, and the FoxO1–Dio2 axis governs TH-induced hypertrophic
growth of neonatal cardiomyocytes in vitro and in vivo. Utilizing transverse aortic constriction
as a model of hemodynamic stress in wild-type and cardiomyocyte-restricted FoxO1 knockout
mice, we unveil an essential role for the FoxO1–Dio2 axis in afterload-induced pathological
cardiac remodeling and activation of TRα1. These findings demonstrate a previously unrec-
ognized FoxO1–Dio2 signaling axis in stress-induced cardiomyocyte growth and remodeling
and intracellular TH homeostasis.
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Heart failure remains a leading cause of death in indus-trialized nations, and the epidemic is rapidly expanding toinclude the developing world1. A variety of disease-related
stimuli, such as myocardial infarction, ischemia, and chronic
hypertension, trigger pathological cardiac remodeling, a process
that often progresses to heart failure and sudden death2–4. Con-
ventional thinking holds that hypertrophic growth of the myo-
cardium is a compensatory response to increases in workload,
serving to minimize wall stress and preserve contractile function.
However, accumulating evidence, both preclinical and epide-
miological, highlights maladaptive features of chronic ventricular
hypertrophy5–7, suggesting that targeting of cardiac hypertrophy
may be a relevant therapeutic goal8. Numerous transcriptional
and signaling pathways have been identified in the regulation of
pathological cardiac remodeling9. Among them, the Forkhead
box O (FoxO) family of transcription factors has emerged as
critical drivers of stress-induced cardiac remodeling10.
FoxO factors are a subclass of the large family of Forkhead
transcriptional regulators characterized by a conserved 110 amino
acid DNA-binding motif called the “forkhead box” or “winged
helix” domain11. The forkhead domain of four members of the
FoxO subgroup (FoxO1, FoxO3, FoxO4, and FoxO6) recognizes a
consensus DNA-binding element, 5′-RYAAAYA-3′ (where R=
A/G, Y= C/T), in numerous genes; indeed, the fact that this
FoxO-responsive element (FRE) is recognized by all FoxO factors
suggests that aspects of their functions overlap12. However, tar-
geted disruption of FoxO1, but not FoxO3 or FoxO4, in mice
causes embryonic lethality due to abnormal cardiovascular and
placental morphogenesis13–16. Moreover, we have recently
reported that FoxO1, but not FoxO3, activity is critically asso-
ciated with metabolic stress-induced pathological remodeling of
the heart17. These observations support a specific role of FoxO1
in cardiovascular morphogenesis and metabolic stress-induced
cardiac remodeling that cannot be compensated by other FoxO
family members18. On the other hand, combined inactivation of
FoxO1 and FoxO3 in adult cardiomyocytes has been shown to
exacerbate ischemic damage to the myocardium19, whereas mice
lacking FoxO4 are resistant to ischemic damage to the heart20.
Moreover, mice lacking FoxO3 are sensitized to transverse aortic
constriction (TAC)-induced cardiac hypertrophy21,22. Collec-
tively, these studies demonstrate an essential but distinct role of
FoxO factors in cardiac remodeling and that the nature of
external stimuli differentially impacts the activity of each FoxO
factor. However, molecular mechanisms underlying FoxO1 action
in stress-induced hypertrophic remodeling of cardiomyocytes
remain largely unknown.
A growing literature points to post-translational modifications,
such as phosphorylation, acetylation, and ubiquitination, as pre-
dominant mechanisms that regulate FoxO activity12,23,24. It is
now well established that phosphorylation of FoxO factors by Akt
following activation of insulin or insulin-like growth factor-1
(IGF-1) receptors negatively regulates FoxO activity, stability, and
subcellular localization11. More recently, thyroid hormones (THs)
have been reported to potentiate FoxO1 activity in hepatocytes by
inhibiting Akt activity25, thereby unfolding another layer of
complexity in the orchestrated control of FoxO activity. The
physiological significance of such a FoxO1–TH signaling axis in
cardiomyocyte heath has yet to be elucidated.
TH has long been implicated in cardiomyocyte health in the
developing, neonatal, and adult heart26. In humans, abnormal TH
levels in the fetus and neonate are linked to multiple cardiovas-
cular complications, including diminished cardiac output and
tachycardia27. Importantly, subtle changes in TH homeostasis are
also intimately linked with cardiovascular disease28,29, high-
lighting the fact that THs are critical regulators of cellular
homeostasis in most tissues30,31. Although circulating levels of
the prohormone 3,5,3′,5′-tetraiodothyronine (thyroxine or T4)
and the active isoform 3,5,3′-L-triiodothyronine (T3) are com-
monly measured clinically to evaluate an individual’s thyroid
status, less well recognized is the fact that THs are metabolized
intracellularly. Specifically, much of TH action in muscle cells is
directly regulated by two important deiodinase enzymes: the type
II iodothyronine deiodinase (Dio2) is involved in active TH
biosynthesis by converting the inactive prohormone T4 to active
isoform T3, and the type III deiodinase (Dio3) inactivates both T4
and T3 (refs. 31,32).
In light of the established roles of both FoxO1 and TH in
disease-related cardiac remodeling, coupled with the interplay
between them in some settings, we set out to address two major
questions: (a) Does a FoxO–Dio2 signaling axis contribute to
stress-induced hypertrophic remodeling of cardiomyocytes? (b)
Does FoxO activity govern deiodinase gene expression in cardi-
omyocytes to regulate TH metabolism? Here, we demonstrate
that FoxO1 activity is essential for reciprocal regulation of Dio2
and Dio3 expression and that the FoxO1–Dio2 signaling axis
governs TH- and stress-induced cardiomyocyte hypertrophic
growth and pathological remodeling of the heart.
Results
FoxO1 governs TH-induced cardiomyocyte growth by inversely
regulating Dio2 and Dio3 expression. To gain insight into the
role of FoxO factors in TH-induced cardiomyocyte growth, we
treated neonatal rat ventricular myocytes (NRVMs) in culture
with control and two sequence-independent FoxO1-specific small
interfering RNAs (siRNAs) and then assessed for TH-induced
NRVM growth using a leucine incorporation assay. We noted
that robust, T4-induced growth of control siRNA-treated cells
was attenuated in FoxO1-deficient cells (Fig. 1a, Supplementary
Fig. 1A). Efficient knockdown of FoxO1 mRNA (Fig. 1b) and
protein (Fig. 1c, d) levels was confirmed using quantitative RT-
PCR (qPCR) and immunoblot analyses, respectively.
Next, we sought to determine whether FoxO1 activity plays a
role in cardiomyocyte growth in response to other stimuli. To test
this, we assessed NRVM growth after treating the cells with a
variety of physiological (IGF-1) and pathological [phenylephrine
(PE) and angiotensin II (Ang II)] hypertrophic agonists. We
noted that unlike T4-induced cardiomyocyte growth, knockdown
of FoxO1 had little impact on the growth response elicited by
other agonists (Fig. 1a). Importantly, NRVM growth in response
to other agonists (e.g. Ang II) in FoxO1-deficient cells trended
toward an increase relative to control siRNA-treated cells (Fig. 1a).
These observations support a specific role of FoxO1 in TH-
induced cardiomyocyte growth and are concordant with our
previous study demonstrating that FoxO1 gain-of-function
inhibits Ang II-induced NRVM growth21.
In addition to T4, knockdown of FoxO1 also resulted in
significant attenuation of T3-induced NRVM growth (Supple-
mentary Fig. 1A). These data suggest that FoxO1-dependent
regulation of intracellular TH metabolism is required for TH-
induced NRVM growth. We, therefore, analyzed mRNA levels of
deiodinase genes associated with TH metabolism and observed
that selective knockdown of FoxO1 significantly attenuated both
Dio2 mRNA (Fig. 1b) and protein (Fig. 1c, d) levels. By contrast,
knockdown of FoxO1 resulted in marked induction of Dio3
expression, whereas Dio1 expression remained unchanged
(Fig. 1b). Based on these findings, we reasoned that induction
of Dio3 in FoxO1-deficient cells may inactivate T3 action. To test
this, we treated cells with control or two sequence-independent
Dio3-specific siRNAs and confirmed efficient knockdown of Dio3
mRNA levels (Supplementary Fig. 1B). Next, NRVMs were
treated with control, FoxO1- or Dio3-specific siRNAs alone or in
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combination, and then assessed T3-induced NRVM growth. We
observed that abrogation of the T3-induced NRVM growth
response in FoxO1-deficient cells was largely rescued by
concomitant knockdown of Dio3, and that T3-induced NRVM
growth was not inhibited in Dio3-deficient cells (Fig. 1e),
suggesting that TH metabolism by deiodinase enzymes plays an
important role in TH-induced cell growth.
It has been reported that FoxO3, a member of the FoxO family
with actions functionally distinct from FoxO1, governs Dio2
expression in skeletal muscle cells33. To test whether FoxO3
activity also governs Dio2 expression in cardiomyocytes, we
depleted cells of FoxO3 using two sequence-independent FoxO3-
specific siRNAs and noted that efficient knockdown of FoxO3 did
not alter Dio2 or Dio3 mRNA levels (Supplementary Fig. 1C); as
expected, however, mRNA levels of two known FoxO3 targets
were significantly attenuated34 (Supplementary Fig. 1D). These
findings suggest that FoxO3 is not the primary regulator of Dio2
in cardiomyocytes. Consistent with this notion, selective knock-
down of FoxO3 did not alter the T4-triggered growth response of
NRVM (Fig. 1f). We conclude that FoxO1, but not FoxO3,
activity inversely regulates Dio2 and Dio3 expression in
cardiomyocytes and that FoxO1–Dio2/Dio3 transcriptional
circuitry governs TH-induced cardiomyocyte growth.
FoxO1–Dio2 axis governs TH-induced hypertrophic growth of
cardiomyocytes. To test further for a specific role of the
FoxO1–Dio2 axis in TH-induced cardiomyocyte remodeling, we
treated NRVM with control or two sequence-independent Dio1-
and Dio2-specific siRNAs. Although efficient knockdown of Dio1
mRNA levels did not affect T4-induced NRVM growth (Sup-
plementary Fig. 2A, B), selective knockdown of Dio2 mRNA
(Fig. 2a) and protein (Supplementary Fig. 2C) blunted T4-















































































































































































Fig. 1 FoxO1 and Dio2/Dio3 transcriptional circuitry govern TH-induced NRVM growth in vitro. a Selective knockdown of FoxO1 in NRVM specifically
abrogated T4-induced hypertrophy but not the cellular growth response triggered by other stimuli. NRVM growth was evaluated by assessing radiolabeled
leucine incorporation into protein following 24 h treatment, where NRVM growth in the control (Cont) siRNA- and vehicle (Veh)-treated cells was
set to 100%. b Selective knockdown of FoxO1 in NRVM resulted in marked reduction of Dio2 mRNA levels and significantly induced Dio3 expression.
c, d Immunoblotting (c) and quantitation (d) of FoxO1 and Dio2 levels in FoxO1-deficient NRVM. e T3-induced growth response of NRVM transfected with
control, Dio3- and FoxO1-specific siRNAs alone or in combination. Note that the abrogation of T3-induced NRVM growth response in FoxO1-deficient cells
was largely rescued in cells transfected with both Dio3- and FoxO1-specific siRNAs. f Selective knockdown of FoxO3 did not affect T4-induced growth
response of NRVM. In all panels, data are depicted as mean ± SEM (n= 3 independent experiments). *p < 0.05 vs control; #p < 0.01 vs control, NS not
statistically significant. Statistical analyses were conducted using a two-tailed, unpaired Student’s t-test.
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Dio3 mRNA levels in Dio2-deficient cells (Fig. 2a) implies that
Dio2 activity is not required for T3-induced cell growth. Indeed,
selective knockdown of Dio2 did not affect T3-induced cell
growth (Fig. 2b). Together, these data further support the notion
that the FoxO1–Dio2 axis plays an important role in TH-induced
cardiomyocyte growth.
Next, we tested the role of the FoxO1–Dio2 axis in
cardiomyocyte growth in vivo. Neonatal mouse cardiomyocytes
manifest robust proliferative capacity for the first few days of
life35. Compared with hypoxic conditions of embryonic heart,
neonatal heart growth takes place in a highly oxidative
environment, and that growth is associated with profound
changes in cardiac contractility in response to increased
metabolic and hemodynamic demand36,37. As FoxOs and TH
are important regulators of metabolic and redox events38, we








































































































































Fig. 2 FoxO1–Dio2 axis governs TH-induced hypertrophic growth of neonatal cardiomyocytes. a qRT-PCR analyses of mRNA levels of the indicated
genes in NRVM transfected with control or two sequence-independent Dio2-specific siRNAs. Note that efficient knockdown of Dio2 did not affect Dio3
expression (n= 3 independent experiments). b Selective knockdown of Dio2 in NRVM abrogated the T4-induced, but not T3-induced, cellular growth
response (n= 3 independent experiments). c Histology (left) (bar= 2mm) and co-immunostaining with anti-pH3 (green) (middle) and anti-cTnT (red)
(right) antibodies of P3 FoxO1-WT (WT) and FoxO1-cKO (cKO) heart. Proliferating cardiomyocytes in LV free wall are shown (arrowhead), and DAPI was
used for the nuclear staining (bar= 10 μm). d Quantitation of proliferating cardiomyocytes in WT and cKO hearts (n= 4), where total number of
proliferating cells in WT hearts was considered to be 100%. Note the significant decrease in proliferating cells in cKO heart. e qRT-PCR analyses of
ventricular mRNA levels of the indicated genes in P3 WT and cKO mice, and mRNA levels of ribosomal 18S was used as control (n= 4). f qRT-PCR
analyses of mRNA levels of the indicated genes in control- and si-FoxO1-transfected NRVM with or without T4 treatment (n= 3 independent
experiments). In all panels, data are depicted as mean ± SEM. *p < 0.05 vs control; **p < 0.01 vs control; #p < 0.001 vs control. Statistical analyses were
conducted using a two-tailed, unpaired Student’s t-test.
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neonatal cardiomyocyte growth. We harvested postnatal day 3
(P3) hearts from wild-type (WT) mice and performed immuno-
histochemical analyses of a mitotic marker (phospho-histone H3,
pH3) and a cardiomyocyte-specific marker (cardiac troponin T).
Dual-positive nuclei were counted as proliferating cardiomyo-
cytes35. Using this technique, we detected large numbers of
proliferating cardiomyocytes in left ventricle (LV) free wall
(Fig. 2c, Supplementary Fig. 2D).
To evaluate FoxO1-specific regulation of cardiomyocyte
proliferation, we crossed mice harboring floxed alleles of FoxO1
(FoxO1L/L)15 (Supplementary Fig. 2E) with αMHC-Cre, a
cardiomyocyte-specific Cre recombinase-expressing mouse line,
to allow for cardiomyocyte-restricted inactivation of FoxO1. The
resulting FoxO1L/L/αMHC-Cre and FoxO1L/L mice are referred to
herein as cKO and WT, respectively. Cardiomyocyte-specific
inactivation of FoxO1 was confirmed using semi-quantitative
PCR comparing Cre-mediated recombination of floxed sites in
the genomic DNA (gDNA) isolated from heart (ventricles) and
tail of WT and cKO mice (Supplementary Fig. 2E, F) as well as
qPCR analyses of ventricular FoxO1 mRNA levels in WT and
cKO hearts (Fig. 2e). We noted that compared with WT hearts,
the number of proliferating cardiomyocytes was significantly
reduced in cKO mice (Fig. 2c, d), coinciding with reciprocal
regulation of Dio2 and Dio3 expression in WT and cKO hearts
(Fig. 2e). These findings support a role for the FoxO1–Dio2/Dio3
axis in redox-induced cardiomyocyte remodeling.
We further noted that compared with vehicle-treated cells, T4
treatment of control siRNA-treated cells induced transcript levels
of two hypertrophic markers, Anf (Nppa) and BNP (Nppb), in
NRVM27, whereas knockdown of FoxO1 markedly attenuated
T4-induced hypertrophic marker expression (Fig. 2f). Together,
we conclude that the FoxO1–Dio2 signaling axis participates in
stress-induced hypertrophic growth of cardiomyocytes.
FoxO1 activity in early post-TAC heart reciprocally regulates
Dio2 and Dio3 expression. To test whether the FoxO1–Dio2
axis also participates in maladaptive cardiomyocyte remodeling
in the setting of disease-related stress, we examined expression
of FoxO1 target genes in LV of WT mice exposed to TAC
surgery, a pressure overload-induced stress model of hyper-
tension causing robust cardiac hypertrophy39,40. Total RNA
was extracted from LVs 4 days post-TAC as well as from
control (sham)-operated mice, and mRNA levels of selected
FoxO1 target genes were evaluated by qPCR. Compared with
sham-operated hearts, we noted robust up-regulation of mRNA
levels of several known FoxO1 targets in TAC LV16,41,42
(Fig. 3a). By contrast, mRNA levels of CamkIIδ and a FoxO3
target, Murf1 (ref.34), were not induced in TAC-stressed LV
(Fig. 3a). These data suggest that activation of select FoxO1
targets in early TAC-stressed LV is not a result of global acti-
vation of gene expression. Immunoblot analyses to monitor
FoxO1 phosphorylation status at Thr24 and Thr32 revealed
significant decreases in phosphorylated (inactive) FoxO1 levels
in TAC-stressed LV protein lysates (Fig. 3b). Together, these
data reveal that pressure overload triggers activation of FoxO1
in early afterload-stressed heart.
We also evaluated expression of the so called “fetal gene
program”, a collection of genes reactivated by pathological stress.
Compared with sham-operated hearts, we observed robust
induction of transcript levels of several hypertrophic markers,
including Myh7 (i.e. β-MHC), Anf (Nppa), BNP (Nppb), and
Rcan1.4 (also called MCIP1), a proxy for calcineurin/NFAT
activity, in TAC hearts, along with a concomitant decrease
in Myh6 (i.e. α-MHC) message (Supplementary Fig. 3A). These
data indicate that in addition to FoxO1, the hypertrophic gene
program and signaling cascade are activated early in load-
stressed LV.
To validate FoxO1-specific activation of its target genes in
cardiomyocytes of stressed heart, we analyzed mRNA levels of
FoxO1 targets in cKO hearts. Cardiomyocyte-specific inactivation
of FoxO1 was confirmed by analyzing Cre-mediated recombina-
tion of floxed sites in genomic DNA of isolated ventricular
cardiomyocytes (Supplementary Fig. 3B) and by immunoblotting
of LV lysates (Supplementary Fig. 3C), respectively. We also
noted that cardiomyocyte-restricted silencing of FoxO1 did not
alter FoxO3 protein levels (Supplementary Fig. 3C). Importantly,
cardiomyocyte-specific inactivation of FoxO1 blunted induction
of its target genes in TAC-stressed LV (Supplementary Fig. 3D),
corroborating FoxO1-specific activation of target genes in
afterload-stressed heart.
Compared with sham-operated heart, we observed significant
increases in Dio2 mRNA levels in TAC-stressed hearts of both
WT and cKO mice; however, induction of Dio2 expression was
significantly attenuated in cKO heart (Fig. 3c). By contrast,
mRNA levels of Dio1 (Supplementary Fig. 3E) and Dio3 (Fig. 3d)
were not induced in TAC-stressed hearts of WT mice, whereas
mRNA levels of Dio3, but not Dio1, in cKO LV were higher at
baseline than in WT littermates and markedly induced in post-
TAC LV (Fig. 3d). Collectively, these data lend strong credence to
our hypothesis that FoxO1 is a primary regulator of reciprocal
expression of Dio2 and Dio3 in cardiomyocytes. We also
hypothesized that FoxO1 is a direct, upstream regulator of the
Dio2 gene.
Sequence analysis revealed two conserved FoxO-responsive
elements (FREs) in the upstream promoter region of the Dio2
gene33 (Supplementary Fig. 3F). Utilizing quantitative analyses of
chromatin immunoprecipitation (ChIP) assays in sham- and
TAC-operated ventricles, we noted significant increases in FoxO1
occupancy at the Dio2 promoter in TAC-stressed hearts
compared with sham or control IgG (Fig. 3e). These data suggest
that FoxO1 binding at the conserved FREs in the upstream Dio2
promoter is required for robust activation of Dio2 expression in
stressed hearts.
To define the specificity of FoxO1 as a transcriptional regulator
of Dio2, we fused the Dio2 promoter to a luciferase reporter
and conducted transcriptional assays. Co-transfection in COS7
cells with a Dio2 reporter construct harboring WT-FREs with
increasing amounts of caFoxO1 expression plasmid resulted in
marked and concentration-dependent induction of luciferase
activity (Fig. 3f). By contrast, mutation of the FREs (Supplemen-
tary Fig. 3G) blunted transcriptional activity (Fig. 3f). Collectively,
these data suggest that FoxO1 binding to the FREs is essential
for its transcriptional activity and robust induction of Dio2
expression in TAC-stressed WT hearts.
FoxO1–Dio2 axis governs TAC-induced cardiac hypertrophy
and contractile dysfunction. To determine the functional sig-
nificance of the FoxO1–Dio2 signaling axis in stress-induced
pathological cardiac hypertrophy, normal chow-fed WT mice
were subjected to sham or TAC surgery. The fetal gene program,
hypertrophic growth, and cardiac function and fibrosis were
evaluated 3 weeks post-TAC surgery, a time point when hyper-
trophic growth reaches steady state43. We noted robust cardiac
hypertrophy, contractile dysfunction, fibrosis and activation of
fibrotic and fetal gene programs in TAC-operated mice when
compared with sham-operated mice (Fig. 4, Supplementary
Fig. 4). By contrast, this hypertrophic phenotype was markedly
attenuated in TAC-operated WT mice fed propylthiouracil (PTU,
a potent inhibitor of deiodinase enzymes)-containing chow for
1 week before being subjected to surgery (Supplementary Fig. 4).
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Consistent with our previous report44, these data support the
notion that attenuation of cardiac hypertrophy in PTU chow-fed
mice was due, in part, to blockade of Dio2-mediated T3 bio-
synthesis, consistent with the role of Dio2, but not Dio1, in TH-
induced NRVM growth (Fig. 2a, Supplementary Fig. 2B) and
robust induction of Dio2 expression in early TAC-stressed hearts
(Fig. 3c).
To test this, we quantified mRNA levels of Dio1 and Dio2 genes
in normal chow-fed WT LVs and noted that relative Dio1
expression is significantly less than that of Dio2 (Supplementary
Fig. 5A). By contrast, semi-quantitative RT-PCR analyses
revealed more Dio1 transcripts than Dio2 in liver (Supplementary
Fig. 5B), implying a tissue-specific differential expression of Dio1
and Dio2 genes. Therefore, we also analyzed Dio1 and Dio2
expression in ventricular cardiomyocytes isolated from sham-
and TAC-operated hearts and noted robust induction of Dio2
(Supplementary Fig. 5C) and a hypertrophic marker βMHC
(Supplementary Fig. 5D) expression in TAC-stressed cardiomyo-
cytes. Importantly, compared with Dio2, Dio1 expression in
isolated cardiomyocytes was essentially undetectable (Supple-
mentary Fig. 5C). Moreover, only T4-induced cell growth was
markedly attenuated when we rendered NRVMs “intracellularly
hypothyroid” by exposing them to PTU (Supplementary Fig. 5E).
On the other hand, selective knockdown of Dio2, but not Dio1,
resulted in T4-induced NRVM growth insensitive to PTU
treatment (Supplementary Fig. 5F). Collectively, these data
further support our hypothesis that the FoxO1–Dio2 axis plays
an essential role in cardiomyocyte TH homeostasis and stress-
induced pathological cardiac hypertrophy.
Pituitary Dio2 activity is critically linked with metabolic stress-
induced adipocyte hypertrophy and obesity45. To exclude a global
















































































































































































Fig. 3 Activation of FoxO1 in early post-TAC heart is required for reciprocal regulation of Dio2 and Dio3 genes expression. a qRT-PCR analyses of
mRNA levels of indicated genes in 4 day TAC- and sham-operated LVs (n= 4). b Immunoblotting (left) and quantitation (right) of total-FoxO1 (T-FoxO1)
and phospho-FoxO1 (p-FoxO1) levels in 4 days TAC- and sham-operated LVs (n= 3). GAPDH was used as a loading control. Average of p-FoxO1/T-FoxO1
and p-FoxO1/GAPDH ratios were used to determine relative p-FoxO1 levels. c, d qRT-PCR analyses of mRNA levels of Dio2 (c) and Dio3 (d) in 4 days TAC-
and sham-operated LVs of FoxO1-WT (WT, n= 12) and FoxO1-cKO (cKO, n= 12) mice. e Quantitative ChIP assays were conducted in 4 day sham- and
TAC-operated ventricles of the WT mice (n= 3). Note the significant increase in FoxO1 occupancy at the Dio2 promoter in TAC hearts. Schematic of Dio2
illustrates that PCR amplification was performed using primers spanning the two FoxO-responsive elements (FREs) in the Dio2 promoter. f Schematic of
Dio2 luciferase vector harboring two FREs. Note that co-transfection of a constitutively active FoxO1 (caFoxO1) elicited significant, concentration-
dependent activation of reporter activity harboring WT, but not mutated, FREs. In all panels, data are depicted as mean ± SEM. *p < 0.05 vs sham/control;
**p < 0.01 vs sham; ***p < 0.0001 vs sham, #p < 0.05 vs WT (f); #p < 0.001 vs control (c). Statistical analyses were conducted using a two-tailed, unpaired
Student’s t-test.
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TAC-induced cardiac hypertrophy in 8- to 10-week-old cKO,
control littermates (WT), and age-matched αMHC-Cre-expressing
control mice (herein termed Cre). Mice of each genotype with
normal cardiac function, as evaluated by transthoracic echocar-
diography, were exposed to TAC surgery along with a cohort
exposed to sham surgery. Echocardiography was performed
3 weeks post-surgery, and body weight was measured prior to
sacrificing the animals to harvest hearts or LVs for further
analysis. Compared with sham-operated hearts, gross analysis and
histology of TAC-stressed hearts of WT mice manifested clear
evidence of robust hypertrophic growth (Fig. 4a). Hypertrophic
growth of post-TAC hearts was also observed in Cre mice
(Supplementary Fig. 6A). By contrast, TAC-induced cardiac
hypertrophy was significantly blunted in cKO mice (Fig. 4a).
These observations were corroborated by measurements of heart
weight/body weight ratios in which control hearts manifested
marked increases (nearly 60%) in size, whereas cKO mice
displayed only modest (~16%) growth (Fig. 4b). To confirm that
this cardiac growth was due to hypertrophic growth of
cardiomyocytes, cross-sectional area (CSA) of ≈100 cardiomyo-
cytes was measured in transverse sections of LV septa stained with
wheat germ agglutinin (Fig. 4c). Compared with sham-operated
WT mice, we observed a modest decrease in heart and
cardiomyocyte size in cKO mice (Fig. 4a, d). However,
cardiomyocytes of both WT and cKO mice manifested significant
increases in CSA after TAC surgery, although that hypertrophic
growth of cardiomyocytes in cKO hearts was attenuated
relative to WT littermates (Fig. 4d). Collectively, our in vitro
and in vivo data suggest that in response to upstream stimuli, the
FoxO1–Dio2 axis acts as an essential driver of cardiomyocyte
hypertrophic growth.
To assess whether TAC-induced increases in FoxO1 activity
are required to promote maladaptive cardiac hypertrophy, we
evaluated cardiac function in conscious mice by transthoracic
echocardiography. Three weeks after TAC surgery, contractile
performance quantified as left ventricular fractional shortening
(FS) was decreased in WT (Fig. 5a, b) and Cre (Supplementary
Fig. 6B) mice compared with sham-operated littermates. Inter-
estingly, the decline in FS after TAC in cKO mice was
significantly less than that in WT mice (Fig. 5a, b). The reduction
in FS after TAC in WT mice was driven by increases in both LV
end-diastolic diameter (LVEDD) and LV end-systolic diameter
(LVESD) (Fig. 5c, d). Importantly, cKO mice did not exhibit
significant change in LVEDD and LVESD compared to sham
(Fig. 5c, d). Together, these data suggest that activation of FoxO1
in cardiomyocytes early after TAC is essential to drive pressure
overload-induced maladaptive cardiac remodeling and contractile
dysfunction.
Ablation of cardiomyocyte FoxO1 attenuates TAC-induced
fetal gene reactivation and cardiac fibrosis. We evaluated
whether attenuation of hypertrophic growth in cKO hearts is













































Fig. 4 FoxO1 is required for pathological cardiomyocyte growth. a Male mice of respective genotypes, FoxO1-WT (WT) and FoxO1-cKO (cKO), were
subjected to sham and TAC surgery. Whole mount (left) and histology (right) of representative 3-week post-sham and -TAC hearts are shown. Note that
cardiomyocyte-specific silencing of FoxO1 (cKO) blunted TAC-induced hypertrophic growth of heart (bar= 2mm). b Heart weight (HW)/body weight
(BW) ratios indicate robust cardiac hypertrophy in WT (n= 16) mice 3-week post-TAC, which is attenuated in cKO mice (n= 18). *p < 0.001 vs sham.
c, d Immunohistochemistry (c) and quantitation (d) of cross-sectional area (CSA) of cardiomyocytes of WT and cKO mice after 3-week sham and TAC
surgery (n= 3). Data are depicted as mean ± SEM. *p < 0.05 vs sham; **p < 0.01 vs sham; ##p < 0.01 vs WT. Statistical analyses were conducted using a
two-tailed, unpaired Student’s t-test.
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Indeed, we noted robust induction of transcript levels of hyper-
trophic markers, including β-MHC, Rcan1.4, and Nppa in Cre
(Supplementary Fig. 6C) and in WT (Fig. 6a–c) TAC hearts,
along with a concomitant decrease in α-MHC message (Supple-
mentary Fig. 7A). By contrast, induction of these genes was
markedly attenuated in cKO TAC heart (Fig. 6a–c). Further, in
contrast with the robust induction of hypertrophic markers in
TAC-stressed WT hearts, expression of Klf15, a transcriptional
inhibitor of pathological cardiac hypertrophy46, was significantly
attenuated in TAC-stressed WT, but not in cKO, hearts (Fig. 6d).
Excessive fibrogenesis due to activation of cardiac fibroblasts in
the setting of disease-related stress contributes to cardiac
contractile and electrical dysfunction and ultimately heart
failure47. Compared with sham-operated hearts, trichrome
staining revealed marked increases in reactive interstitial fibrosis
in TAC-stressed hearts of Cre (Supplementary Fig. 6D) and WT
mice (Supplementary Fig. 7B). In contrast, interstitial fibrosis was
essentially absent in TAC-stressed cKO hearts (Supplementary
Fig. 7B). The increases in cardiac fibrosis coincided with
significant induction of transcript levels of fibrotic genes,
including Colα1, Ctgf1, and α-SMA in TAC-stressed WT LV,
but not cKO, mice (Fig. 6e, f, Supplementary Fig. 7C). These data
support the notion that mice lacking FoxO1 in cardiomyocytes
are less susceptible to pressure overload-induced maladaptive
cardiac remodeling, hypertrophy-associated gene expression, and
fibrosis.
FoxO1-dependent induction of Dio2 governs intracellular
TH action via TH-responsive gene expression. TH triggers
cellular growth by activating mitogen activated protein kinases
(MAPK, e.g. ERK1/2)48, transcriptional activity of the thyroid
hormone receptor (THR), the FoxO1–Akt signaling axis, and
autophagy26,28,29. Importantly, pathological cardiac remodeling
has been reported to be associated with induced Dio2 expres-
sion49, p38-dependent repression of Klf15 expression50, and
increased autophagic activity51 in hearts. In light of this, and
having detected reduced Klf15 expression (Fig. 6d) and increased
autophagic activity51 in WT TAC hearts, we tested whether ERK
activity is also increased in load-stressed hypertrophic hearts.
Immunoblotting of LV lysates revealed increased ERK activity in
WT TAC hearts, a change not seen in cKO TAC hearts (Sup-
plementary Fig. 8A). Importantly, increased Dio2 expression in
































































Fig. 5 FoxO1-cKO hearts manifest preserved contractile function in
response to TAC. a Representative M-mode tracings of 3-week sham- and
TAC-operated hearts of FoxO1-WT (WT) and FoxO1-cKO (cKO) mice.
b Percent of left ventricular fractional shortening (%FS) of WT (n= 16) and
cKO (n= 20). c Left ventricular end-diastolic diameter (LVEDD, mm) of
WT (n= 14) and cKO (n= 20), and d Left ventricular end-systolic diameter
(LVESD, mm) of WT (n= 14) and cKO (n= 19) are shown. Note that cKO
mice do not manifest contractile dysfunction when compared with WT
littermates TAC heart. In all panels, data are depicted as mean ± SEM. *p <
0.01 vs sham; ***p < 0.001 vs sham; ##p < 0.0001 vs cKO; NS not
statistically significant. Statistical analyses were conducted using a two-


































































































































































Fig. 6 Reactivation of fetal and fibrotic gene programs in response to
TAC is blunted in cKO hearts. a–f qRT-PCR analyses of mRNA levels of the
indicated genes in 3-week TAC and sham LVs of FoxO1-WT [WT, n= 13
(a), 12 (b, c), and 14 (d–f)] and FoxO1-cKO [cKO, n= 13 (a), 12 (b, c), and
14 (d–f)] mice. mRNA levels of ribosomal 18S were used as control. In all
panels, data are depicted as mean ± SEM. *p < 0.05 vs Sham; **p < 0.01 vs
sham; ***p < 0.001 vs sham; #p < 0.05 vs WT, ##p < 0.001 vs WT; NS not
statistically significant. Statistical analyses were conducted using a two-
tailed, unpaired Student’s t-test.
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of mRNA levels of Mag, an established THR downstream tar-
get52, only in WT TAC hearts (Supplementary Fig. 8B).
These data suggest that activation of THR is associated with
FoxO1–Dio2 axis-mediated increases in local active TH levels.
However, we found that quantification of T3 or T4 levels in
sham- and TAC-operated LV lysates was technically challenging,
possibly due to the extremely short half-life of T3 in rodents53 as
well as T3/T4 contamination from blood and non-cardiomyocyte
cells in LV tissue. This may explain why cardiomyocyte-specific
overexpression of Dio2 in mice yielded modest increases in
cardiac T3 levels without changing cardiac or circulating T4
levels54.
To test whether FoxO1-dependent induction of Dio2 is linked
to T3-dependent activation of THR, we first employed a FoxO1
gain-of-function strategy in NRVMs. We found that compared
with control (LacZ) protein, adenovirus-mediated overexpression
of caFoxO1 in NRVMs resulted in marked increases in both Dio2
protein (Fig. 7a) and mRNA (Fig. 7b). By contrast, overexpression
of FoxO1 significantly attenuated Dio3 expression (Fig. 7b). Next,
we conducted in vitro transcriptional assays and tested the
contribution of the FoxO1–Dio2 axis to THR-dependent reporter
gene expression (Supplementary Fig. 8C). We noted that addition
of T4 to HEK293 cells, co-transfected with a luciferase vector
harboring two TH-responsive elements (TREs) along with
expression plasmids for TRα1, the predominant isoform of THR
in cardiomyocytes28,29, and caFoxO1 resulted in significant and
concentration-dependent induction of luciferase activity (Supple-
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Fig. 7 FoxO1-dependent induction of Dio2 governs TH-responsive gene expression in hypertrophic cardiomyocytes. a, b caFoxO1 overexpression in
NRVM markedly induced Dio2 protein (a) and mRNA (b) levels but repressed Dio3 gene expression (b). c Schematic of thyroid hormone receptor (THR)-
responsive reporter plasmid harboring two thyroid hormone-responsive elements (TREs). Note that co-expression of caFoxO1 and THRα1 (TRα1), but not
either alone, in HEK293 cells resulted in robust and synergistic activation of reporter activity only in the presence of T4 (n= 3). d, e THR-responsive
reporter activity in NRVM transfected with control or indicated gene-specific (FoxO1 and Dio2) siRNAs. Note that compared with control siRNA-treated
cells, selective knockdown of FoxO1 (d) and Dio2 (e) significantly attenuated T4-dependent activation of luciferase activity. In all panels, data are depicted
as mean ± SEM (n= 3 independent experiments). *p < 0.05 vs control; **p < 0.001 vs control; #p < 0.001 vs control; ###p < 0.0001 vs control. Statistical
analyses were conducted using a two-tailed, unpaired Student’s t-test. f Working model for FoxO1’s role in adaptive and maladaptive hypertrophic growth
of cardiomyocytes. In response to oxidative- and TAC-induced (Stress), activation of FoxO1 and FoxO1-dependent reciprocal regulation of Dio2 and Dio3 in
cardiomyocytes is a key driver for subsequent activation of other transcriptional and signaling programs to activate fetal and fibrotic genes, which together
ultimately lead to adaptive and maladaptive hypertrophic growth of neonatal and adult cardiomyocytes, respectively.
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induction of Dio2 is required to potentiate TRα1 activity in the
presence of T4.
To test this further, we transfected luciferase vector alone or in
combination with TRα1, caFoxO1, or both, and assessed
luciferase activity. We observed that co-transfection of both
FoxO1 and TRα1 was essential for robust and synergistic
activation of luciferase activity in the presence of T4, whereas
addition of T4 resulted in modest induction of luciferase activity
in cells co-transfected with TRα1 alone (Fig. 7c). By contrast,
addition of T4 had no effect on basal luciferase activity or in cells
co-transfected with FoxO1 alone (Fig. 7c), suggesting exogenous
TRα1-dependent induction of reporter activity. Furthermore,
increased luciferase activity elicited by FoxO1 may stem from a
cryptic FoxO1 binding site within the luciferase vector.
Finally, we analyzed THR-responsive reporter luciferase activity
in FoxO1- and Dio2-deficient NRVMs (Supplementary Fig. 8C).
We noted that addition of T4 resulted in robust induction of
reporter activity in control siRNA-treated cells (Fig. 7d, e),
indicating that endogenous Dio2 activity was sufficient to activate
TRα1 transcriptional activity. Consistent with this notion, T4-
dependent activation of reporter activity was blunted in both
FoxO1- (Fig. 7d) and Dio2-specific (Fig. 7e) siRNA-treated cells,
respectively. However, selective knockdown of FoxO1 and Dio2
had only a modest effect on basal reporter activity (Fig. 7d, e).
These data suggest that Dio2-dependent increases in intracellular
active TH levels (i.e. T4 to T3 conversion) are essential for T4-
dependent activation of reporter activity. To probe this notion
further, as well as test the physiological relevance of PTU action
on Dio2 to attenuate stress-induced cardiac hypertrophy, we
evaluated whether PTU can inhibit T4-dependent activation of
reporter activity and whether that inhibitory effect of PTU can be
rescued by T3 (Supplementary Fig. 8C). Indeed, we noted
concentration-dependent inhibition of TH-responsive reporter
activity by PTU, whereas addition of T3 along with the highest
dose of PTU resulted in complete rescue of reporter activity
(Supplementary Fig. 8E). Taken together, our findings support a
model in which FoxO1-dependent reciprocal regulation of Dio2
and Dio3 modulates intracellular TH metabolism, contributing
importantly to stress-dependent adaptive or maladaptive hyper-
trophic growth of cardiomyocytes (Fig. 7f).
Discussion
This study unveils a FoxO1–Dio2 signaling axis as a previously
unrecognized mechanism of stress-induced adaptive and mala-
daptive remodeling of cardiomyocytes (Fig. 7f). Specifically, we
report five important findings. First, we report that FoxO1, but
not FoxO3, activity is essential for reciprocal regulation of Dio2
and Dio3 gene expression in cardiomyocytes. Second, utilizing
FoxO1 loss- and gain-of-function strategies, we have identified
Dio2 as a direct downstream target of FoxO1 and observe that
FoxO1 binding to a conserved FRE within the Dio2 promoter is
required to activate Dio2 expression. Third, we have discovered a
previously unrecognized FoxO1–Dio2 axis as a critical driver of
TH-induced cardiomyocyte growth. Fourth, we have discovered
activation of FoxO1 in early post-TAC heart, a finding corrobo-
rated by analysis of global gene expression patterns55. Moreover,
load-induced expression of FoxO1 targets was blunted in cKO
mice, pointing to FoxO1 specificity. Fifth, we have uncovered an
essential role for TAC-induced activation of FoxO1 in patholo-
gical cardiac remodeling, with afterload-induced cardiomyocyte
growth and remodeling significantly blunted in mice in which
FoxO1 was silenced selectively in cardiomyocytes. Furthermore,
we report that both pharmacological inactivation of Dio2 activity
or depletion of Dio2 levels attenuated cardiomyocyte hyper-
trophic growth and TH-responsive gene expression. Finally and
from a larger perspective, our findings highlight the importance
of intracellular TH homeostasis and metabolism in the cellular
response to disease-related stress.
Disease-related stress elicits a maladaptive myocardial remo-
deling response that is associated with activation of a fetal gene
program, fibrosis, contractile dysfunction, and cardiomyocyte
hypertrophy, which together culminate ultimately in heart failure,
a huge burden on individuals and society1. In order to con-
template suppression of pathological cardiac remodeling as a
therapeutic intervention, identification and elucidation of prox-
imal triggers are required. Given the established roles of FoxO
transcription factors in a wide array of cellular functions and
organ homeostasis12, we set out to decipher the role and mole-
cular mechanisms of FoxO1 action in pathological cardiac
remodeling in the setting of the clinically prevalent circumstance
of elevated afterload (e.g. hypertension).
FoxO1 phosphorylation by Akt and deacetylation by Sirt1 are the
most widely studied mechanisms of FoxO1 inactivation24 and
activation56, respectively. Recently reported studies, however, have
uncovered significant cooperativity between TH and Sirt1 in FoxO1
activation by inhibiting Akt function57. As such, data reported here
support a functional link between FoxO1 and TH in gene expres-
sion and cellular growth. Several lines of evidence support the
notion that early activation of FoxO1 in load-stressed heart is a
major driver of TAC-induced pathological cardiac remodeling,
including decreased FoxO1 phosphorylation and attenuation of
TAC-induced induction of select FoxO1 target expression in cKO
TAC heart. Furthermore, genetic inactivation of FoxO1 in cardio-
myocytes blunted TAC-induced cardiomyocyte hypertrophic
growth, reactivation of the fetal gene program, elicitation of cardiac
fibrosis and contractile dysfunction. Although the precise
mechanism of FoxO1 activation in early post-TAC heart remains
unclear, it is plausible that cooperative actions of TH and Sirt1
contribute by suppressing Akt activity. This notion is supported by
the observation that mice lacking Akt1 are sensitized to TAC-
induced hypertrophy58, whereas mice lacking Sirt1 manifest resis-
tance to cardiac hypertrophy59. However, we cannot formally rule
out a possible role of yet unidentified factor(s) in this phenomenon.
Reciprocal regulation of Dio2 and Dio3 expression in skeletal
muscle cells by FoxO3 has been reported to govern skeletal
muscle cell growth and regeneration33,60. Utilizing FoxO loss-
and gain-of-function strategies, we have uncovered that FoxO1,
but not FoxO3, is primarily involved in reciprocal regulation of
Dio2 and Dio3 expression in stressed cardiomyocytes. Impor-
tantly, FoxO1 activity had no significant effects on Dio1 expres-
sion in cardiomyocytes. Moreover, several lines of evidence
support the notion that FoxO1 is a direct, upstream regulator of
the Dio2 gene in cardiomyocytes. Collectively, our data have
identified a previously unrecognized FoxO1–Dio2 axis critically
involved in stress-induced adaptive and maladaptive growth of
cardiomyocytes. Thus, our study and previously reported work in
skeletal muscle33,60 highlight a specific and essential role for
FoxO1 and FoxO3 in intracellular TH homeostasis in cardiac and
skeletal muscle cells, respectively. Presently, it is unknown whe-
ther FoxO factor-mediated reciprocal regulation of Dio2 and Dio3
expression in distinct muscle cell types is context dependent or
responsive to yet unidentified cell-specific co-factor(s).
Pathological stress-induced cardiac hypertrophy is known to be
governed by the intricate and highly orchestrated actions of
numerous transcriptional, signaling, and metabolic events and
epigenetic modifications of chromatin structure9. In addition, TH
signaling and TRα1 activity are intimately linked to both phy-
siological and pathological cardiac growth28,29. In heart failure
patients, circulating TH levels are often low28,29, whereas Dio2
expression increases in pathologically hypertrophied heart49. On
the other hand, gain or loss of TRα1 activity can potentiate and
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prevent pathological cardiac hypertrophy, respectively61, sug-
gesting that intracellular TH status is an important and inde-
pendent determinant of cardiomyocyte health. Although it has
been reported that elevated T3 levels improve contractile activity
of hypertrophic cardiomyocytes54, other studies demonstrated
that T3 treatment had no62, or detrimental63,64, effects on con-
tractile activity in hypertrophied heart. Together, these studies
suggest that the beneficial and detrimental effects of TH depend
on the nature of the stress and the extent and duration of
exposure, thereby underscoring the complexities of TH actions in
cardiac remodeling. Of note, treating heart failure patients with
TH has been limited due, in part, to cardiotoxic actions64.
Several lines of evidence, including attenuation of T4-induced
NRVM growth in Dio2-, but not Dio1-, deficient cells and robust
induction of Dio2, but not Dio1, expression in TAC-stressed
hearts and cardiomyocytes, suggest strongly that Dio2 is the
primary deiodinase enzyme involved in intracellular TH meta-
bolism and homeostasis. Moreover, attenuation of TH-responsive
reporter activity in PTU-treated and in Dio2-deficient cardio-
myocytes, as well as TAC-induced cardiac hypertrophy in PTU
chow-fed WT mice, collectively provide additional credence to
the notion that PTU-dependent inhibition of Dio2 activity is
intimately linked to attenuation of TAC-induced cardiomyocyte
growth. These results are consistent with a prior study49
demonstrating that PTU treatment significantly blunted oxidative
stress-induced cardiac damage and remodeling. Importantly,
oxidative stress resulted in robust elevation of Dio2, but not Dio1,
expression and cardiac T3 levels in hypertrophic heart, which
were blocked by PTU treatment49.
Several studies, however, have reported that the deiodination
activity of Dio2 in tissue homogenates is insensitive to PTU or
requires high concentrations of PTU for efficacy65–67. This dis-
crepancy could be related to the fact that an unidentified cellular
reducing factor is critical for efficient Dio2 deiodination activity
in vivo65. To mimic in vivo conditions, most in vitro studies
therefore incorporate high concentrations of the reducing che-
mical, dithiothreitol (DTT), to activate Dio2 activity within the
homogenate. Of note is the fact that PTU is known to compete
with DTT65. Moreover, subtle differences between Dio1 and Dio2
in the amino acid sequences around the enzymatic active site have
profound effects on Dio2’s affinity for DTT as well as its PTU
sensitivity65. For example, Dio1 activity of Tilapia is insensitive to
PTU in vitro65,68. Subsequently, it was reported that the PTU-
insensitive nature of Tilapia Dio1 is not due to a serine-to-proline
substitution at position 128 within the enzymatic active site (as
compared with other mammalian Dio1 enzymes), but rather
stems from differences in amino acid sequence elsewhere within
the protein68. Mammalian Dio2 also harbors a proline at that
position65. Therefore, it will be important to determine whether
the unidentified cellular reducing factor and DTT activate
Dio2 similarly and whether PTU differentially affects Dio2
activity in vitro and in vivo. Future work will be essential to assess
PTU-dependent inhibition of Dio2 activity without DTT49.
We have uncovered a specific and previously unrecognized
FoxO1–TH signaling cascade that is critically involved in
hypertrophic and pathological remodeling of the heart. We have
identified Dio2 as a direct downstream target of FoxO1 and
unveiled the circuitry whereby FoxO1-dependent reciprocal reg-
ulation of Dio2 and Dio3 expression is a critical driver in TH-
induced cardiomyocyte growth. Further, our findings highlight
the importance of intracellular TH homeostasis in the cellular
response to disease-related stress. These findings have potential
therapeutic relevance, as we69–71 and others72 have reported that
both genetic and pharmacological inhibition of histone deacety-
lase activity blunts, and can even reverse, stress-induced cardiac
remodeling. Given that acetylation and deacetylation modulate
FoxO1 transcriptional activity and deiodinase gene expression24,
our findings point to potential translational strategies involving
small molecules in current clinical use.
Methods
Animals, echocardiography, and TAC. To generate cardiomyocyte-specific
FoxO1 knockout (cKO) animals, mice harboring a floxed FoxO1 allele were crossed
with αMHC-Cre transgenic mice. FoxO1-cKO and corresponding control floxed or
αMHC-Cre mice were maintained on an FVB genetic background. The cKO mice
were fertile and developed normally with no apparent cardiovascular phenotype.
Transthoracic echocardiography was performed on conscious, gently restrained
mice using Sonos 5500 and VisualSonic Vevo 2100 systems73. Briefly, LVEDD and
LVESD were measured from M-mode traces recorded at the level of the papillary
muscles before and 3 weeks after surgery. Fractional shortening (FS) was calculated
as (LVEDD− LVESD)/LVEDD and expressed as a percentage. Male mice
(8–10 weeks old) of respective genotypes with normal FS were subjected to pressure
overload by TAC along with a cohort exposed to sham (control) surgery51. At
defined time points, animals were euthanized and whole heart or LV were collected
for histological, molecular, and biochemical analyses. All mice were maintained
according to the guidelines of the Care and Use of Laboratory Animals published
by the US National Institutes of Health and the Institutional Animal Care and Use
Committee, and all procedures were approved by the Institutional Ethics Review
Committee of the University of Texas Southwestern Medical Center.
Neonatal cardiomyocyte isolation, transfection and adenovirus infection.
Primary NRVM were isolated and cultured in Dulbecco’s modified Eagle’s medium
(DMEM)/M199 (3:1) containing 3% fetal bovine serum (FBS) and antibiotics74.
For gene knockdown, NRVM were transfected with two sequence-independent,
gene-specific siRNAs (Sigma) using Lipofectamine RNAiMax (Invitrogen) in Opti-
MEM (Gibco). After 6 h, cells were washed twice with growth medium and cul-
tured overnight in growth medium. For adenovirus-mediated protein over-
expression, cells were incubated for 1 h with adenovirus at a multiplicity of
infection of 50 plaque-forming units per cell. Cells were then washed twice with
fresh serum-free DMEM/M199 medium and cultured for an additional 24 h. Under
these conditions, infection efficiency routinely exceeded 90%.
RNA and genomic DNA isolation for semi- and quantitative reverse tran-
scription PCR. Total RNA (0.3–1 μg) isolated from neonatal mouse ventricles,
adult LV, liver, adult ventricular cardiomyocytes, and NRVM was used to prepare
cDNA using the iScript cDNA synthesis kit (Bio-Rad)74. Real time PCR and semi-
quantitative PCR was performed using 5- to 10-fold diluted cDNA, Taqman or
gene-specific primers and SYBR Green on a Roche light cycler 480. Primer
sequences are provided in Supplementary Table 1. Ribosomal 18S RNA and actin
were used as control for quantitative and semi-quantitative analyses, respectively.
Quantitation of mRNA levels of specific genes was analyzed using a ΔΔCt method.
Genomic DNA (gDNA) from neonatal mouse ventricle, tail, and adult
ventricular cardiomyocytes was isolated using Quick-DNA miniprep plus kit
according to the manufacturer’s instructions (Zymo Research). Semi-quantitative
PCR analyses using equal amounts of gDNA (10–100 ng) from WT and cKO mice
were used to assess Cre-mediated recombination of loxP sites in the FoxO1 gene.
PTU treatment. TH deficiency was induced by feeding animals for the indicated
durations with iodine-free chow supplemented with 0.15% PTU purchased from
Harlan Teklad Co. (TD 97061) (Madison, WI). Mice, fed normal or PTU chow for a
week, were subjected to sham or TAC surgery and followed for 3 weeks. Hearts and/
or LVs were harvested to evaluate cardiac hypertrophy, fibrosis, and gene expression.
Immunoblotting. Whole-cell lysates of mouse LV and NRVMs were prepared in
T-PER (Thermo) containing protease and phosphatase inhibitors (Roche). Nuclear
fractions of heart 4 days following sham- or TAC procedures were prepared using
NE-PER nuclear cytoplasmic extraction reagents according to the manufacturer’s
instructions (Thermo). Equal amounts of protein (3–10 μg) were separated on a
4–20% SDS-PAGE gel (Bio-Rad), transferred to a nitrocellulose membrane, and
immunoblotted to detect and quantify specific protein bands using an Odyssey
scanner (LI-COR version 3)74. Proteins were detected with a 1000-fold dilution of
the following primary antibodies: FoxO1 (#2880, Cell Signaling and ab39670;
Abcam); Phospho-FoxO1 (#9464, Cell Signaling), ERK (#4695, Cell Signaling);
Phospho-ERK (#4370, Cell Signaling); 10,000-fold dilution of GAPDH (10R-
G109a, Fitzgerald) and tubulin (ab6046; Abcam) and 500-dilution of Dio2 antibody
(ab77481, Abcam) antibodies, respectively.
[3H]Leucine incorporation. Leucine incorporation was determined in NRVMs
transfected with control or gene-specific siRNAs. After transfection in Opti-MEM,
cells were cultured in serum-free medium for 24 h, washed three times with serum-
free medium, and then treated with either vehicle or T4 or T3 (100 nM), Ang II
(200 nM), IGF-1 (50 nM), and PE (50 µM)70. In some assays, NRVMs were
transfected with control or gene-specific siRNA and TH-induced NRVM growth
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was assessed in the presence of DMSO (vehicle) or PTU (0.5 mM). Relative growth
of control siRNA-transfected and vehicle-treated NRVMs was set to 100%.
Histology and immunohistochemistry. Histology and immunohistochemical
(IHC) analyses were performed with formaldehyde-fixed hearts and processed as
routine paraffin sections74. Briefly, hearts were fixed in 4% paraformaldehyde
overnight at 4 °C and transferred to 1× PBS, followed by paraffin embedding. After
deparaffinization and antigen retrieval, hematoxylin/eosin staining was performed
for morphological analysis. Wheat germ agglutinin was used for CSA measure-
ments, quantified from at least 30 cells per section and three independent heart
sections per group. Masson trichrome staining was used for measurements of
fibrosis. IHC analyses of phospho-histone 3 and cardiac troponin T were per-
formed to detect proliferating cardiomyocytes35 and DAPI was used to stain nuclei.
Luciferase and ChIP assay. Transcriptional assays using pDR4, a luciferase vector
harboring two TREs with or without constitutively active FoxO1 (caFoxO1) and
TR1α expression vectors, were performed in HEK293 (Clontech; cat# 632271) and
NRVM. Plasmids were transfected into HEK293 cells using Fugene HD (Roche)75.
On the other hand, pDR4 luciferase vector was transfected into NRVM using
Lipofectamin 2000 (Invitrogen). Luciferase assays using a 700-bp Dio2 reporter
construct harboring WT or mutated FoxO-response elements (FRE) were per-
formed in COS7 cells (ATCC; CRL-1651) with or without caFoxO1. Luciferase
activity with or without TH and PTU treatment was measured using dual luciferase
kit (Promega) and normalized with renilla activity16. All cell lines tested negative
for mycoplasma contamination.
Quantitative analyses of ChIP assays were conducted to assess FoxO1
occupancy at the Dio2 promoter in ventricular tissues of Sham and TAC-operated
mice (4 days) using the Zymo-Spin ChIP kit according to the manufacturer’s
instructions (Epigenetics)74. Briefly, isolated ventricular tissues were minced and
exposed to 1% formaldehyde with gentle shaking (15 min, RT). After quenching
the crosslinking reaction with glycine, tissue was washed twice with PBS, and then
homogenized in nuclear extraction buffer. The homogenate was centrifuged
(10 min, 500g, 4 °C) and the supernatant was discarded. The nuclear pellet was
resuspended in nuclear lysis buffer, sonicated, and centrifuged (15 min, 12,000g,
4 °C) to prepare chromatin solution. Chromatin solution was diluted 10-fold and
incubated with control (IgG) and FoxO1 sera (3 μg) overnight at 4 °C with rotation.
DNA purified from chromatin solutions was used as input. Purified DNA with or
without immunoprecipitation was used to determine relative FoxO1 occupancy by
comparing the Ct value of 30-fold diluted input DNA with undiluted
immunoprecipitated DNA samples in control (IgG) and FoxO1 sera.
Statistical analysis. Data are presented as mean ± S.E.M. of multiple independent
replicates. Data were analyzed using GraphPad Prism software 8.0 and statistical
analyses were conducted by the two-tailed, unpaired Student's t-test for experi-
ments with two groups. Values of p ≤ 0.05 were considered statistically significant.
All experiments were performed with at least three biological replicates. No sta-
tistical analysis was performed to predetermine sample sizes. Mice were randomly
assigned to experimental and control groups. Investigators were blinded to the
genotypes of animal during the experiments and outcome assessments.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its Supplementary Information. Each data point corresponding to
figures that describe the results from in vivo and/or in vitro model studies are provided as
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